• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Treatment of melanoma with IL-36

Research Project

Project/Area Number 18K08262
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 53050:Dermatology-related
Research InstitutionTohoku University

Principal Investigator

Numasaki Muneo  東北大学, 大学病院, 准教授 (50344677)

Co-Investigator(Kenkyū-buntansha) 藤村 卓  東北大学, 大学病院, 講師 (50396496)
Project Period (FY) 2018-04-01 – 2021-03-31
Project Status Completed (Fiscal Year 2020)
Budget Amount *help
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥260,000 (Direct Cost: ¥200,000、Indirect Cost: ¥60,000)
Fiscal Year 2019: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2018: ¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
KeywordsIL-36β / 悪性黒色腫 / PD-1 / サイトカイン / 血管新生 / 腫瘍免疫 / 免疫遺伝子治療
Outline of Final Research Achievements

IL-36β is produced by bronchial epithelial cells and dendritic cells. To examine the anti-tumor activity of IL-36 β, we constructed two types of recombinant retroviral vector DFG-PTH-truncated IL-36β-IRES-Neo and DFG-GH-truncated IL-36β-IRES-Neocarrying truncated IL-36β, and transduced into B16-F10 melanoma cells. Established B16-F10-PTH-truncated IL-36β cells and B16-F10-GH-truncated IL-36β cells grew very slowly compared with that of parental B16-F10 cells in vivo. We examined the mechanisms of anti-tumor effects of truncated IL-36β, and found that truncated IL-36β could down-regulate the surface expression levels of programmed cell death (PD)-1 on CD4 and CD8 T cells stimulated by anti-CD3 monoclonal antibody and anti-CD28 monoclonal antibody.

Academic Significance and Societal Importance of the Research Achievements

IL-36β は抗癌作用を有しており、その抗癌機序として CD4 および CD8 T 細胞上の免疫チェックポイント分子 PD-1 の発現を低下させる作用が関与している可能性が示唆された。
今後 IL-36β が CD4 および CD8 T 細胞上の PD-1 の発現を低下させる作用の機序を解明すれば、新たな公害材の開発につながる可能性がある。

Report

(3 results)
  • 2020 Final Research Report ( PDF )
  • 2019 Research-status Report
  • 2018 Research-status Report
  • Research Products

    (6 results)

All 2019 2018

All Journal Article (3 results) (of which Peer Reviewed: 2 results) Presentation (2 results) Patent(Industrial Property Rights) (1 results)

  • [Journal Article] Impaired antigen‐specific lymphocyte priming in mice after Toll‐like receptor 4 activation via induction of monocytic myeloid‐derived suppressor cells2019

    • Author(s)
      Tsukamoto Hiroki、Kozakai Sao、Kobayashi Yohei、Takanashi Risako、Aoyagi Takuya、Numasaki Muneo、Ohta Shoichiro、Tomioka Yoshihisa
    • Journal Title

      European Journal of Immunology

      Volume: 49 Issue: 4 Pages: 546-563

    • DOI

      10.1002/eji.201847805

    • Related Report
      2019 Research-status Report 2018 Research-status Report
    • Peer Reviewed
  • [Journal Article] Could problem lists summarize comprehensive geriatric assessments? A nationwide cross-sectional survey on geriatricians' attitudes towards problem lists.2019

    • Author(s)
      Tomita N, Kojima T, Ishiki A, Ueda J, Numasaki M, Okinaga S, Akishita M, Arai H.
    • Journal Title

      Geriatr. Gerontol. Int.

      Volume: 19(2) Issue: 2 Pages: 159-164

    • DOI

      10.1111/ggi.13574

    • Related Report
      2019 Research-status Report 2018 Research-status Report
    • Peer Reviewed
  • [Journal Article] Overuse/Underuse を見逃さないプロのみかたと対処法 抗認知症薬2019

    • Author(s)
      沼崎宗夫、石木愛子、冨田尚希、冲永壮治、荒井啓行
    • Journal Title

      薬局

      Volume: 70 (2) Pages: 273-278

    • Related Report
      2019 Research-status Report
  • [Presentation] IL-32γの過剰発現は、悪性胸膜中皮腫の増殖とVEGFおよびIL-8の産生に影響を与える2018

    • Author(s)
      沼崎宗夫、富岡佳久
    • Organizer
      第77回日本癌学会学術総会
    • Related Report
      2018 Research-status Report
  • [Presentation] 東日本大震災被災地居住高齢者における、認知機能低下の割合とその経時的変化2018

    • Author(s)
      植田寿里、石木愛子、冲永壯治、冨田尚希、沼崎宗夫、古川勝敏、荒井啓行
    • Organizer
      第8回日本認知症予防学会学術集会
    • Related Report
      2018 Research-status Report
  • [Patent(Industrial Property Rights)] 抗腫瘍剤及び腫瘍を治療するための医薬組成物2019

    • Inventor(s)
      沼崎宗夫
    • Industrial Property Rights Holder
      東北大学
    • Industrial Property Rights Type
      特許
    • Filing Date
      2019
    • Related Report
      2019 Research-status Report

URL: 

Published: 2018-04-23   Modified: 2024-12-25  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi